Schedule 13D ownership disclosure
AVENUE THERAPEUTICS, INC.
Common Stock, $0.0001 Par Value · CUSIP: 05360L403
Event date: 2024-12-31
- Filing-level shares
- 295,022.00
- Percent of class
- 13.8%
- Fortress Biotech, Inc.Reported CIK 0001429260
Shares: 295,022.00 · Class: 13.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-000898
- Form type
- SCHEDULE 13D/A
- Filer
- AVENUE THERAPEUTICS, INC.
- CIK
- CIK 1644963
- Filed
- Jan 03, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13D beneficial ownership